Transfusion 1998: Vol 38 Index

23 Pages·1998·9.4 MB·English

SUBJECT INDEX: VOLUME 38(1998)
In the subject index, the page number refers to the first page of the In Volume 38 (1998), Number One (January) contains pages 1-117;
communication in which the subject is addressed rather than to the Number Two (February), pages 118-220; Number Three (March),
specific page on which the referenced key words can be found. An “L” pages 221-322; Number Four (April), pages 323-418; Number Five
in parentheses following the page number indicates that the subject (May), pages 419-516; Number Six (June), pages 517-618; Number
entry appeared in a letter to the editor; an “E” in parentheses indicates Seven (July), pages 619-706; Number Eight (August), pages 707-802;
that the subject was discussed in an editorial; a “/” between numbers Number Nine (September), pages 803-898; Number Ten (October),
indicates on what page the correction for the subject entry appears. pages 899-996; Number Eleven/Twelve (November/December), pages
997-1152.
A GRE IRNS aoeo cae coca dad ascaxdcadccdss ueeridsnincchan chsecssatasebvanicucsteampynoe e 378
jig) So) ee : hepatitis C virus, 378, 1097
in animals, ... WEIN CORON a ccc stsnscacc ano neseosatensibcaaaiid 378, 1097
antibodies, Albumin. See also Human albumin
biochemical nature, as predictor of CD34+ cell collection efficiency, ................:+0++. 1046
bone, plasma exchange,
cardiovascular tissue, transmissible spongiform encephalopathy
corneal tissue, Allele-specific polymerase chain reaction, .
genetic regulation, C733G (Leu245Val) polymorphism,
human cell and tissue distribution, D-CB RyDrid GRODS,, «..isci0c.<seseecere0e
DVII, T329C mutation in exon 2,
G1006T (Gly336Cys) polymorphism, .
A transferase, cisAB blood type, HLA typing,
ABO incompatibility Allele-specific primer polymerase chain reaction
ARIE MR RIMINI) 5S 0 S00 cS Cv cen case tvsn cjendasasschoscasshadsntndncsbooncsbeaiateamctnnecee 51 Duffy blood group locus,
bedside test for, Duffy (Fy) blood group system, ..
bone transplantation, ... ethnic population,
cornea transplantation, .. Fe y receptor IIA polymorphism, ...
heart transplant, FcyRila receptor,
hemolytic transfusion reaction, .... FY glycoprotein, ........
ESPACE MRPNNTIR TRIE 255 visasc posscubcdauancianssesusiscocetevsteaetnenaterehive 975 immunohematology,
ABO testing Y chromosome in sample of female blood, ...............:.s:sesseseeee: 104]
MR eae casas Sonik dew iva scasscusadsaasecaborenticdsaedises 999(E), 1030, 1071 Allergic reaction
EARNER RAMONE 5 case ceca scscasvstsecnestdesaadeetastnsactucsantaniocdeensees 343 duration of platelet storage, ....
ABO-incompatible plasma lymphocytotoxic antibody,
NPR MN 2c 2Ss es ckcashikocincocchiccc seadesontsgesimaenn eexade 51 Allogeneic blood transfusion
YD RAN I MNOERRUNNN = orcas v bbc n Sass decia sndasusabcctaivnanca snunaasdbaocecn utadinesr sea ct 51 Ss Re Oe eked SRD D te ree ee ee aR eR SE set :
ERUREINNPETICIET CENEEIOIECAUIOED <5. sessed eis ssciasnncusapccoodceesc doievisssaizcaaendcaeses s 51 perceptions of,
IRACNEtTl yU RMMERRNEIN so ieb 033s acs baaaducavebvaniesa¥ cuckesssabanvdoesinensesstasseanece 318(L) physician recommendations,
Activated partial thromboplastin time, effect of red prevention of graft-versus-host disease,
Ei ADMIRE OER Do oo nos occ po da tan <osevayou navaxeustigabchennaceieacecemeee 1011 Allogeneic cell contamination of sample for
AAEM geas o cota nsncyaienadisansasesiteenasddsoacedcensasdharasodest¥axecousees 999(E), 1071 POOR YISNGUASE CALAIEN RO CC NONE a5 oa ackccsacnsdacsnsnnsocescatzotarecevosstion 1041
PO ANN PIR RCI 055 svc naxe<acbsesondancsicnsesseocss susesesatadansneeasaeee 517(E) Alloimmunization to multiple red cell antigens, 1022,1026
Acute normovolemic hemodilution, .................sssscsssscesssseesceeceerenees 400 American Association of Blood Banks
advantages,
as alternative to allogeneic blood transfusion, functions,
clinical studies, future directions
hemorrhage history, ...
PROPERIE S WO IEMARIOI D scar cusiiosacssqnsnsacccdasadessnsuscivancnsecoodavevassen 135 major activities,
management,
preoperative autologous blood donation, compared, standards for prevention of graft-versus-host disease,
Pe RN aga es ite socnn ous sank sasslase sad asunstcduonstes Ghusmnsdendeseteassacccseor’ 924 American Association of Blood Banks institutional member,
aR MRINNCN ME Susie tscssan5scsdneaadadoove ceadninneiseusecsbsascqavesinactase 473 home transfusion
AGCUte thrombosis, anitithroDmin i Uf, ........:c.cccsaccassessassssasssscesscrsoreesen 481 component issued, PANES oteen en Sehr b RRO Dee 90
Administration error reporting system, ...............++. seserre TOO(E), 1030; 1071
blood component preparation SysteM, ............:sssseeeeseneeneeeeees 860 informed consent,
Food and Drug Administration patient diagnosis,
EFTOLTEPOMING SYSLEM, .......-:....ccccescescescesesses 999(E), 1030,1071 posttransfusion visit,
regulation of blood bank software, ..............sssscsssseceseeeeeees 86 transfusionists, ss :
home transfusion, nationwide SUIVEY, .............ssceseeseeeeeseeeeeeeeees 90 NONE CEINUEINDD sca pases esp stan tsceana quelo ceacameesaneratuaidancndsone 90
ISO 9000 registration, 75, 79 American Medical Association, Council on Scientific Affairs,
no-fault compensation in Italy, ...............ssccscsssssesssserssseserseceres DIO report on crossover use of donated blood for autologous
Adsol red cell unit, transfusion,
Adult T-cell leukemia, American National Standards Institute, ...............:sccssssseesesseseceeseeeeeees 5
Africa Amicus blood cell separator
human T-iymphotropic virus type I, in 1969, AS.TEC 204 blood cell separator, compared, ... tee
human T-lymphotropic virus type II, in 1969, blood collection, .. 285
Alanine aminotransferase evaluation, .. 848
blood donor, Brazil, platelet collection,
Volume 38, November/December 1998 TRANSFUSION
SUBJECT INDEX
REI MDIRRENORSION,, con ocacsvcdeocesccssccssexssseuptoovsnicsertesssesiobecsaneny 848 Antithrombin III
IEEE IERIE ors foc skiosn es euesc n acoasenssdsostusesacnsdvansécstecssansbessboaal 848 acute thrombosis,
ASN NNN UNRINE p05 o puch owe cabcsssssanconoveuspsccbveiscentesstsrenshelen 285 bone marrow transplant-related venooclusive disease,
component yields, .............. delivery,
double apheresis platelet, disseminated intravascular coagulation, .......
incidence of donor reactions, drug-induced deficiency,
incidence of transfusion recipient reactions, extracorporeal circuit,
BURNIN IOR MRM Siso cciny cs skabeescsocoulecensopetsanszerisossiceo MPR ORI ceo nts acs aa ss cavtsnsesdesecs Pes dasauedessucoanesbalssccescacubvonstths 48]
residual white cells, ............ heparin resistance,
RIN ENT ANENNOME TNO 5 665043 ccm overniccucerscncescneeossdusesogsionashsnenebs 285 L-Ase therapy,
GRMN SINC TOIS TURN oc vscedsssacssteasedssissescusesaccedsncssesessserese 848 LeVeen peritoneovenous shunt, ..
white cell contamination, ................sceseeeseeees liver dysfunction,
Spectra Leukocyte Reduction System, compared, liver transplantation,
PARMAR OMAIS cv sass goaPeccennee acu cbaosdcssndcesevesssseehooschcseans ocivavccasestshetaeaveangiats 60 neonatal,
Analysis of errors in transfusion, ...........sscscseeseeseeees 999(E),1030,1071 oral contraceptive, ..................04
Anemia perioperative period,
SRRTINMINSES Ls). sek aiinsunnssonanasennsickicnevtusussnnsiénssssunssennessusnoubsevessaveivenspavags 602 pregnancy,
nitric oxide,
renal dysfunction,
perioperative blood conservation,
structure,
red cell transfusion,
Antithrombin III concentrate,
Angioedema, hepatitis G virus, ...........
acquired deficiency states, ..............
Angiotensin-converting enzyme inhibitor,
congenital deficiency, .
hypotensive reaction,
PARE oS. ccs iecescovassdneoncss oe
red cells filtered at the bedside,
PERRIN asf sacs c css as cavecencss pass sastasaveteaterton tees cho ccuaysas eioregai coset 951
red cells filtered before storage, .......
Anxiety, in donors positive for human T-lymphotropic virus, ..... 1056
Apheresis,
adverse effects
Antibody identification, p values
Antibody screening. ............. CR TIERINs ENOCLEC CERIO 555655022055 a cicapcdibiecvasseuhcweouenstveasessnucesieets 938
RMN RNN esac ccsSka tc 23 pd Lads cet cls caccd onischs pa velcadnacatpeabiaaldeoaha 938
POURED WANE SOON, a ocs sec csnescnscucscinpacsissectoesss “
column agglutination technology, ...........:.:csssssseseeeeeeeeseeseseeeess 959 RON VERIPUNCHETE SYIRPIOINS, <...0..5000i0ssccssssnssscesesessssecuensneess 938
pretransfusion testing instrument, ................00 picrevceusnaseleeerste 959 pain or hematoma at venipuncture Site, ...........cseesseeeeeeees 938
PRA AMMLIURIUCTUSOMEUNE, (35085 cuscassicsonsassasssensoscessccebssbossoctsniccseees 511(L) platelet loss,
Antibody to hepatitis B core antigen procedure-specific rates Mi aoe 938
hepatitis B surface antigen mutant fOrM, .............ccseeseeeseeeeeeesees 56 unconsciousness, sesistdiedemed 938
screening, anticoagulant,
Antibody to hepatitis B e antigen, hepatitis B surface CB Ra URN ENRIRRINC oo 2 3s singe dsNesckcsabdbesangacaavsazexcesaxtensvatvecnlore 16
BRNOI EA IRENES EO RERID oop ooo sabe c deex e ndetioucsscconsssubovsencsubtstecconensolonmant 56 chemotaxin,
PASTIME, GIMEDORESIS 5a ss cecsvsccsasonceicsstinssccessccccncincssepsebensies 318(L) UUs s cass be veaatecot Sodaeas us a LAeesei gas cipnctttapexasptesasaiasivatsnesienl 944
HU eB a to se cssascancdeack peeau susie paseespitcds cues onStaiicl udesuntaceceaeenneEnS 318(L) granulocyte—colony-stimulating factor
delayed hemolytic transfusion reaction, ........... granulocyte collection efficiency, ................:::0 957, LOAE
SIAUUMMOCYIS CONCCHOR VICI, ..0<<..si<scsenessensoessesscsseseacortarasscessel Oe
OOO IERIE io isos scscascicnosnosscooncsvenoninasascsie hematocrit,
systemic inflammatory response syndrome mediator, higher interface offset,
Anti-D preparation platelet count,
Anti-D prophylaxis, consensus conference red cell volume,
antenatal anti-D prophylaxis, improved blood flow during,
ethical considerations of anti-D provision peripheral blood stem cell
SPY UMNMDI MAAC S WASTANESINISES 555 ss Sch ckcpsssuinsnip sasvcccaveasasssaseacuesstes 7 age-specific intra-apheresis recruitment, .............::cseseseeeee 944
Fema RE ara sc bek cake ccuds aes cas Si SACU A cp castesneaienbanietne ed 944, 1046, 1063
immune-mediated thrombocytopenia, CEE TRODE MEA osc ss cs Snnkdnéscesusicescasibicdsiansises convtsupvueastaaveseests 944
UNINRO RN R 5 pce 65 scehccn cékccrdascoredstoesessaccteceiastoenxcsasiahte 97 COHSCHOR CHICICRCY,. ....cscisessseccscessssesasseess 944, 1046, 1051, 1063
MPM IIRRINRMENER NN 55 ssc syns vencessstsennccynatatssivinbestyaucdbssnaadstetbacspeeaien 97 colony-forming units—granulocyte-macrophage, .. 944, 1063
RNR ait seinssievavcaness 1022, 1026 comparison of systems,
Anti-Dob, 1022, 1026 granulocyte—colony-stimulating
Anti-E2 enzyme-linked immunosorbent assay RN aos a ne eshcu sastactpacsbesOoensiaausoncsveasees 944, 1046, 1051, 1063
GB virus type C IDEDEAIMAE UMMM AMIDE oso cen ss cis os seunsscusacvastiescissciasupsbonivedsqesctevsenteuses 944
hepatitis G Virus, .............0.. selective enrichment of more immature progenitors, ...... 1063
Anti-human immunodeficiency v aie PODER Se eR <évadatcn cscs SccopsusiasaseW sbusaniadcagsaeda tuntaninnanatners 24
Anti-humanimmunodeficiencyvirus- 1/2 enzyme immunoassay, ... platelet concentrate, transforming growth factor betal. .......... 156
PU PENEE E R EINE 555055 cis cvensesececsaseesarscensiusntsivasseensesnisonserned terminal complement complex,
Anti-Jkb red cell alloantibody, . “= thrombopoietin,
PARAEE=i ANGE GIRMADTARSIIIIAN, c, <<<: c0seesesscvecosonsossqexscvesesssnespnstgnicsessecestes SRRINDS CREM EINON oon ocencbcdeius sscsxsdosinasereseete :
FUERTET A FOG GEM AMOAIMEMIOY 5.650550 cscscesccssscosesevecsatensvevstesezensacsosoeeres Apheresis platelet
Antimicrobial therapy, thrombotic thrombocytopenia, ABS OATCG SALON DIABINIAS 5.5.45 dssssesecidsscesssopssuancsxacnesasssscasesssssusees 5]
Anti-P1 RUDUEMII NNN Sono cctracs aes dsr cxatann otcissek icedtha sbsuedinphigwassasencciiessieseieeaiven 51
OpT e NE sn 2c oops nao Syed cache sodas nuances sors cavenvasoreora non-group O autologous bone marrow transplant, ...............06 51
RCINGIVUIC THANSIUSION TEACHION, «2. .......s.0c0ccsascocssestiesossossosssasstvess Apheresis system, selective enrichment of more immature
MN Napali cca aoe ar nies apces oar ise Soadabstginn ss wuabaascccnceccedscucssvueucesssesnrtes : BRM NMNINIIN Sooner cxaccsarcadsecesn tet teckposindvinsiandsetdasgns iGasarcdviednsaesddsecaecnessas s 1063
indirect antiglobulin test, ................... Apheresis system, white cell-reduced platelet component
indirect Monocyte MONOlayer ASSAY, .............seceseeeeseeeseeeeeeeeeees MIRE SAE TEMRI SS.Gc asschdctp co erescaievcscrey scacccanncleadp easiubatretcacconndiss luodslosaNG es 966
polyspecific anti-human globulin, .................ccscscssscsssseseeeeeeees CS NI oes coset cets sncoesysccspccasasy Cisevsesodenessincnadinasa 966
reacting at 37°C OCPER EPRI N MAE CATI ENN y 3 5yo cahcseconcn agus scesesecacthonntisaacépsntasassenscshanaseenseié 966
transfusion complications, ......... = determination of degree of conformance with standards, ....... 966
AMUN re UE PUNRONR RIN URUNN SE oasscaen sssdedasnenotonans.oadecuson coscroe® 373 DENI RININE RAMEN yoo cassia ccceSis sacs enesssaanteervesconarssscsviacatnsseied 966
1132 TRANSFUSION Volume 38, November/December 1998
SUBJECT INDEX
validation, SAMI oto bib ais cassie seabiia cc ainobacpadeveae emia een ‘
Apoptosis ofw hite cells in stored red Cells, .............:ssssseseeseeeeeeenes 1082 ae rs aa nee SERS TORS ee 975
Aprotinin,
Artificial organ transplant, cardiovascular tissue, ....
AS104 apheresis machine, pediatric leukapheresis, corneal tissue, ...............
AS.TEC 204 blood cell separator SI NON sis bi cccchccasocecsasiicsccatinsccensatesantaaiaiic headpates 975
Amicus blood cell separator, compared, human cell and tissue distribution, .............ccceseeseseneeeeeeeee 975
blood collection, in human fetal development, ...............:.cccsccsseseseeees 975
platelet collection, SIMI saa atesda a testa etpictad es tninic asks Aickei ctal cab eniaeaahaoceueuuataamaatas 975
component quality, BE REGEIGIIGEs GEST RRC CYO G iiss sn scscssan cccaccedorscnsvicadentocdiaceeens 44]
platelet yield, Ii PN NINN at cop scence san sain cheng na cacwesisincaiaeontelad 1090
separation efficiency, ‘3 Bacteria
WIEIEES COINCOMMMITIINAUION, ...5..000cessssescsssesosssvevasovssesseevstsisdsesesa 285 automated microbiologic blood culture device
ATP, red cell, 24-hour storage at 25°C, ......:.......sssssossssscsssesceseasscessece 424 CRN Sing occ isos la cacanin tcl ctaccensindbstnsccno 674, 1090
Australia platelet component,
GB virus type C,
sampling times,
hepatitis G virus,
human albumin,
Autoimmune hemolytic anemia, .................
WON schavisesectecciacccocasteccastsasstatanstonalesetiens 999(E)), 1030, 1071
red cell-bound immunoprotein, .................ssscsssssscsrsssssssesereseres 782
Bacteriophage inactivation, dimethylmethylene blue. .................. 729
Autologous blood donation
Bacteriophage R17, dimethylmethylene blue, .......0.........cesesceeesees 729
adverse events in donors with cardiac disease, ..............:sse0es00 669
Baumgartner perfusion chambet, ............:.sscssssseseeeeseseeees 997(E), 1004
cardiac disease, safety,
Bedside pretransfusion check, ...........:.sescssssseeeeeeeeees 999(E), 1030, 1071
cardiac surgery,
Behavior, human, classification off or error reporting, .... 999(E),1071
crossover use,
Biological response modifiers and white cell apoptosis in
costs,
SUM I gins soca incndsqnsenntatectactidentlsebtascuiastenestsacétennivisiek 1082
UMPIRES cise ad'casn sevksvececsasnnioanacghbacddastodsucdbuesckaevseelle s 891
Bleeding time, effect of red cell transfusion on,.....
potential risks,
donor perceptions,
IU oo acdc cesisanacsceovanasesectoacaccpusedaeanciteetsaa s 757 Blood bank software, Food and Drug Administration
CUMIN DisP RAN RNR 556 iis laos scans saci statacssinacntennomision 86
erythropoiesis, compensatory, ..............0000 .. 613(L)
hip surgery, interhospital variations, ..............ssssssseseseeeeeeeeeees 530 internationally developed software. .......
FiGSPItAl- SEEING GIMETENCES, ..........00:..secesencascsnsasscsseccasasessanseasors 530 MOOI haps each cst rcecncdoahnbis & pdsackeas deen besenoaaanSbacaasedrecesetoxegen’ 86
iron supplementation, ee TU 556s ss cnnnecat cicssentiqarvuoucjasasnctansbenadenadeeaetdcataseaete 86
intravenous iron, 764 RAINE IIR giao ccirastncssssiovnensdinacnincscdigehavablesasakalsnadiasioeicnsinks 86
OYEP ATOR SUPICTICTUUBEIONS; .0.0..i050<scnsescceessesesessasescaseaserszeeseses 764 Blood cell analyzer and contamination of sample for
knee surgery, interhospital variations, ... 530 Pn RRC GHIMINN POCO NIN cscs ccsenvecnoctavacasdecropiicnccscincectassinccaics 1041
motivations, 757 Blood cell separator, ................0000+ 24, 285, 848, 944, 1046, 1051, 1063
PGR GaARy OOMIMINICTIOIMUIONS, 62.. 02<ses0<<0seceassesccsoseacastaasssactsncessese tat See also Specific type
prostatectomy, 924 RNR scl Sidi csncsdencndaadtomuenacatagedsnoalcasiesoaqvasnsnctonhe 4s
requirements, 891 IRR EIS oc cacconnkoisastaxkdcgicsicincneitctesMandadosindmsoomnannnnit 625
standards, 891 Blood component
Autologous blood transfusion A SPRRRUR INC MUNG TURR OE dia ka occas caniccincencncacenicensnscoroocnresensens 540
adverse reaction, cellular, irradiation for prevention ofg raft-versus-host
SAMS RI NENANLNR NIA Sin cacabases sayadessciutess aravixsbsdscuatncnskssatcsnscdsasilt e 2 CEN Ss robnavens tensctashscindacccmnnceanesstodipacasacssseiess-dusniuatinnaseanntaal 1117(L)
evaluation at large academic hospital,
CPTI BRR CO isk cise cise accccsencisccsainsiavansndornmentesecins 424
cryopreservation
incidence at large academic hospital, . dimethyl sulfoxide concentration, ............ssscssecesseseeeeeeeeees 160
annotated bibliography, second-messenger effectors, ............
TE basics cass veanscicsnsseseccsscsess single-donor platelet, ..................+. we
TFANSTUSION COMPHCAON, ........0:0.6s.c.cescesesseccassoases Cg ar sc cikin cde recitcdierepraceomresstadiaemaaoonnen
Automated microbiologic blood culture device, ...............0. 674, 1090 CN CURRIN 5a csas scacsvnencicstnsapriccorsindcadecannasannreeiae 1090
Enterococcus faecalis, I econ ctnastieskctsacinesinoncars
Escherichia coli, .... 674, 1090 granulocytes,
Pseudomonas putida, ... WIGN IN oscsSos ssssces ann secapas lanes canst cs baabia seachctnassttocesaneoancte 713
Staphylococcus QUIUS, .........00+000+ nucleic acid testing, committee report, .....
Staphylococcus epiderMidis, ...........11000000 Ns pei lecse inctirdoscacivnancc toad CaSkcoacaictnaoaa ngaktebueosneldtanceieone ai a ae
AutoPBSC system, collection of CD34+ cells, ..........ccsesssseseseseseees 1051 BUUREN ONIN cess iss csicncticiaccusnsesesnduactincosneninbintainieeetstatenntia 16
AutoVue System platelet storage, .............
antibody screen, red cell, ..
crossmatch, ......... storage,
oS EEE SSIS Drep enaiershete wovseromeont ett crn orn ree nnn 959 transmissible spongiform encephalopathy
MR REIRSON 6055-9705 snscuskseses soxcstlecoveeasaksisanasnauesuaamantacdetaayy 959 Cohn plasma fraction. ..........
PMU 52s sus sons cenadng sas thé soeseacseet kceneaueonaticonsacaecontiiaa 959
distribution ofi nfectivity, ....
ERT NONI cs 3sscctacoccascaausacs..<d6dnsaubeansouaseranas titeminopemsageanis 959 experimental models, ................-s.ccscscecsessesesesee
Rh type, SI aa cid phics cicncscaicndactsadencleceiniocsieinanaesionts
variant A antigen, United States, 1994...........
variant D antigen, BUR WEREUD PRNN PE RORY |5c ss sn cicsonsnisescovadsscenceusciensereracasersivswonend 31
weak A antigen, ....... white cell reduction in platelet components,
weak D antigen, NUNN CN cache ris cascade cndscpateenrnacneteneenties
B white cell-reduced red cell,
B antigen, white cells and false-positive result in BacT/Alert system,
in animals, white cells in fresh-frozen plasma,
Blood component preparation system
Volume 38, November/December 1998 TRANSFUSION 1133
SUBJECT INDEX
administration, Fepeat TeplaceMienit GCOWONMS, :...<50.0.:.0sscececesssesserseeseactesseteowsseses 368
buffy coat method, replacement-donor effect vs. new-donor effect, .............. 368
component specifications, retention rate, . 368
efficiency, .............. safer replacement-donor subgroup, ..........::scccesessesseseeeseeee 368
process costs, ESaI a aaasc ac gatoak saeco ates ceutoneivecesshayiedavacvaiced subleactepsatsesscnuesee ene
Blood donor. See also Autologous blood donation reticulated platelet,
adverse events in donors with cardiac disease, safe donors
alanine aminotransferase, Brazil, IS PMNRNN ys hes scckslic jens ssad puss seca psRancvaiusSiseilcceceuessiicclbsbwiaagctieersts anes
all-volunteer blood supply, GORAERIOAY CRIVERIO ICDS 6a sis esisaccsnccsensssciacisassigiesosssessaseensstcsice acne
apheresis donors INEHUON LO CORGIS ASAIN, (siu csccsseccsisasicesisssssesssvesesesscsssseisnassve OOS
CSG CRU EAR oo br 938 physical effects of blood donation, .............cccseeseseseteeeeeees BOD
GSMENTIS B SUTACE ABBED, 25555 -5.5065s-sc25.sssesccececasssesessocssesiecses GOO PUN FCN ROS ARANCNIN 2 ose a scsdsvais atcteswscacetcystonscevendeusencncovebe 359
incidence of human immunodeficiency virus, . URI gsc cocsehosdecs cesnceaecseces
incidence of human T-lymphotropic virus, test results as motivation,
incidence ofv iral infections, ..............sceeeeees
PYEVAICTICE OFV IEAISTECCHIONS, ...55.000.<sasieceisnensesronecevessoseossosesss 350
ASURRIPIIOTOCG TASK PHEAVIONS) 65.6 <..oncssc0ecasscnssenpscscsossnqeesseccenvesyscs GOO
whole-blood donors compared, ................004
attitudes about exporting and importing blood, ... voluntary nonremunerated,
INTIME ere carte continent eatans ae puss asus nSansbesesbeaoaicabenabesoons : RNS ysc aset beds ic vauesale wn cosccssnatss
aa aae M NNN INE RINBIDDD 5297805 press ausqsos—scbasinnci-caatec cnsncossdnassuapiohoadswacsaceueetiuns 45 ethical aspects,
community service credit, 45 lower risk,
AAUU AEN N ESB RINN oc esesccvbachocsssns consstualapsciasosiniseghsitasconapeess 271 UIDA REERa N ORNS goo 5 scab sas br hansa cuasresdadsavessccnseseosuntncgssbabacwecsea’
deferral whole-blood donors
deferral status understanding, APHETESIS COMGIS COMPALOG soc c.céssicissscncecscvcsnonsasesnssssarssesees SOD
NATE Gis csc cance en ccbanasctcnveacseesesonsssivanesraccueue 181 CETELEAINE TISK: DEMAVIONS, 030 i0ssecocssescsssencoseasessessessenseassessceensrs GOO
permanently deferred donors, PURERR NON RAO NS yoo cree cons cops cacauscnsenddscnsasudencniesisancsevesseclcagtcoseny, ROM
reasons for, hepatitis Bisurlace ANUpen, .........0:sssosisoscescesensececsssssencsasscesvave GOO
BSEROUBA DEs IDNA coc ans dn ove hccnenccscwobeduepuvalivaseseuarsnterecien 45 incidence of human immunodeficiency virus, .................... 350
recruitment of deferred GONOT, .......:::....:.ccsscssosssessessesenses incidence of human T-lymphotropic virus, ... 350, 1118(L)
return donation motivation of deferred donors, INGAGENCE GLVIFALIMIECTIONS, <..:2.-0.0:.-c-cscceenssiaceccosssesaseseescectess SOU.
short-term temporary deferral effect on future donation, .. 18 prevalence ofv iral infections, ...................cssssscssssssssssssesssssers SOO
deferral registry, CUES PTO TISNCICIAVIONS, 5esccsccciseasassssusseccasupissasssvescsencecseeess 350
RINRRINMENNII 5so o cbse css ap sacs dyn ca uacndadesaos Saatensasetiacenpasvaryeees VAPISETHAE CIRO TOO NNUO cou ooi 3 case sasnssdeds ssa siansegsusvagssosasienctecsnsonsiays 511(L)
Precheck system, .... Blood grouping, bedside as ABO check, ...» 999(E), 1030, 1071
donation experience, ... Blood oxygen,
donor platelet count effects on platelet yields, ..... Blood transfusion. See also Specific type
hip replacement, prospective validation of point score system
GB agent BOOB VIRN OINIG 55a sae a crcscas sssnsetevesayegs sn ceoadssacsapacsdssdnoscdelascdsyasetes 932
infectivity, knee replacement, prospective validation of point score system
WUA MEN oot ose Sccbesevszsbavecsousnseesees ROOT UINCUAM AMIR poses sscsdarainns ces cyasscntnacakdletecasevedeuncceeduceniasteconcieessgees 932
volunteer blood donors in Taiwan, Bone
hemoglobin PMR RSERONN ccs cecotos Sut Va ape ncapSecasaceed, diay pocasesweiedeeataauseeeeckeeaeede 975
URN NIRA MANOT REUER DTN 025 2s aca chcospncoves stic ousksonilendsspevesonauoen 855 BS RBRINCIRA soos as sascn ss cine sesnceadayaucsnstcndspsbnesinaisseccededvesscdicsissiesubsssvenaes 975
female plateletpheresis donors. .......... immunogenic properties ofr ed cell antigens, .............ceeeeeee 975
frequency of donor reactions, ............. Bone marrowtransplantation. Seealso Unrelated-donboorn e marrow
hemoglobin cutoffo f 12.5 g per dl transplantation
standards of the American Association of Blood Banks, CORINA SSPUNTINOD y i oscs iss sseccscievecsetesecivessatcvusnsescoscesessacsaconsel 247
RMSPIMENMMNNS ACUMEN 52 56s doses aisoiscsssvetvsozhegeessnbouxesedoocs 512(L), 1097 immune hemolytic anemia
hepatitis G virus ABO-incompatible allogeneic,
WRU a 5a cpasiacnnsiecssyevedcasacackcossessacavienie , ... 290, 1097 multiple red cell alloantibodies, ....................
PRINN UR a coon o css ian nauh spaces av bp vdeo soseessec’s .. 290, 1097 platelet survival,
volunteer blood donors in Taiwan, ...............sssssssseseeseseesenees 290 platelet transfusion,
human immunodeficiency virus veniooclusive disease, antithrombin III,
donor selection criteria identification, .............csseeeeeeeees 279 Bone transplantation, ABO incompatibility,
exclusion strategy, Bovine spongiform encephalopathy,
risk factors in first-time blood donors in Zimbabwe, . Bovine virus diarrhea, dimethylmethylene blue, .................::c00 729
self-administered survey, Brazil
human T-lymphotropic virus, 1056, 1118(L) alanine aminotransferase, 410(L)
incentives. See also Specific type 45, 323(E). Trypanosoma cruzi, 611(L)
intranasal drug use, .... Breast cancer patients, immunomagneticselecotf iCDo3n4+ cells, .... 1063
iron supplementation, .. Bristol card ABO compatibility test Card, 00.0.0... cceseeeeseesesesseseeeees 1030
monetary incentives, Bufty coat method, blood component preparation system, .......... 860
safety record, component specifications,
transfusion risk, ....... efficiency,
new recruitment strategies, Pa os seo as oats cnt ec taesda sc avonceds voascdnsesha seshsesusiuqsenses cachiveste 860
nonmonetary incentives, ... Buffy coat method platelet concentrate
BoM UMMM N 5 oo dae con san cscnesccaydatovevecnsssieisoydoansecceeabaconeel 1056 C3 activation product,
paid “pedigree” donors, chemotaxin,
perceptions about resource sharing, complement activation,
peripheral blood stem cell, .... .. 944, 1046, 1051 cytokine mRNA,
IEMA TNNRMNNMN osc ss scakc sc acccbacteasicciscévasscasecddtesysdoitolouaaees 368 filtration,
EMER RURIINY) Saco csccisencscccoi «asiostsinasa isantccbcsskcecattotssoeanieesccesell e 368 interferony,
1134 TRANSFUSION Volume 38, November/December 1998
SUBJECT INDEX
EL) | Ee eee pee Se RE SCLEEf r ERTS R EET CREO OI a 236 Fe ec Ne OTE OST TOON TS 385
interleukin-2, colony-forming units—granulocyte macrophage, ... 385, 1063
interleukin-6, comparison of apheresis systems, ...............:csssesceseeseeeeeeees 1051
interleukin-8, UN basics css ia ccovenedesdioncenahesstawsbacieielalinsicanenseee 385
quality, engraftment, 385, 1063
storage, DN 56s sas esis ececssssnsacenccrcosseciagianaauasianedicnmdeneeee 385
terminal complement complex, . RHOMOMMICICAR Coll, oo... scccacecncnsssseoiss 385, 1046
PEEMISTORIEINIG SG OWER LR CIOL), .c.cicn-scsnsceccecsesesencscoenccunsnsascatateads 156 Tao oes co enin scarica ons usc beeidaiecdaesan tee 385
RI Na NR eR ENE ON cise nds sins scans enccpaiennsdanecnecondesesasaabectiad 236 Ne rN os icstia ac risis apncsnscimmmsencaniestaceastngnates 385, 1046
white cell reduction, ................. platelet, time to engraftment, .0..............ecesesecseseseseeeeeees 385, 1063
PIVP IE OUGIVE TEACHIONS, o.icc..ccscncsssnnsciacnsssesscdsasessdactsseseies 410(L) Opa ee NI NINN hic Seton encesy andoscecevenncepsnadavabciensatinnne 1, 1063
white cell subset, RIE NN sa cecescss gatas ssi cndcscadensusdacenstevevdasexstesrnantettend 1063
white cell-reduction filter, burst-forming units—erythroid, . 199, 1063
granulocyte, hematopoietic recovery, . 199, 1063
monocyte, neutrophils, «.........2..000.0+:
Burst-forming units—erythroid, CD34+ cell selection, ........ 199, 1063 a ESSER Rey CE ENESCnee eOe Or es 199
RUUNRURNEMERERE EIRCOLVORY,, xcs csanciavcs ascudeasiccsceasacsnsiscselacossseceoetoantc 199 colony-forming units of multiple lineages, ..................s:ccseseeeee 199
a oa CESS TES eT Aor ROE ere eet ae 199 colony-forming units—granulocyte-macrophage. ........ 199, 1063
reticulocytes, 199 hematopoietic recovery,
Bystander immune Hemolysis, ...........:s0..cesiccsssercscsasnssesseesasciassen’ 225(E) Ho)
OU ONN ainNisnc os Sthe sii ices da aga 199
C
effectiveness in purging
C1 inhibitor concentrate, hereditary angioedema
CRIME CNN cases dac ea cabs cates o okra s iiclassa SG aaa catesd acaiaigiacecee avail 60
CEMRORN RN eee ca le coen onsen cana socntaastewicaked.daesonvtateinsusienesoeeels 540
CUIBTNON CEB os acca scovsesescecsn
FARMSIONI AEE: COMENOMCC CEMA, 6. o.55550s-csnsnscssonsnssanceatasectentecieadsonsees 540
granulocyte—colony-stimulating factor, 60, 1046, 1051, 1063
FECOVErY OF atittponicC I MNIDIIOL, .......2...0c...coceccssseossnesssocesceceses 540 immunoglobulin light-chain variable region genes, .................. 60
recovery Of funCHONal CP INMIDIOT, «..:.05...0623s.esesrssesesecersssasereees 540
RA CRANE NU TRG oi oc csocncsecsaninenbscniavolascestagiess 60
ROTOR C0 NR INEIENINS oc5.c o oe de cneus éns csx acctneech acatccasseaécouackucaccsseacs 540 FYIIOCWE , ..c0scnsccsacsansesensses ..-. 60
RRR eres seta tee eas ace phen canada ston cass casc endcxecsdatece Coeveaveneasieseactuisadeee 540 NUUMN MSI pects cisco censhn art idadidaasn ica conentaskesepteaewraitnacacmsesaaee 60
UELSSPS NGS aS he ain egrets Mens Srv nee ptsae Pe LOO 540 MUU ONMRINN ects cascs cs ees pes ss Sacrede t Na asec la nnbaonasaeeaseanti gaa eee 60
C3 activation product peripheral blood stem and progenitor cell, .... 199, 1046, 1051, 1063
SRI MRN rse soos co tnacascec ciara aus cbsacs pencestun as tapeeeea sas ene aaa 16 platelet, .................
platelet concentrate, ... eee | platelet recovery,
NNER ROR TINTRDEINE os ca.6255s'nccuscenrsdscetvetc Uzeecayalspotdesnstensmaenwnvcnndioe d 16 SUMNER CURIE MO RMNIN O y inca sts ones cscncsiccconexadeascsemdcvnantatoeredats 1046
C3a-desArg hp eRe BRR ehn O Sn Hl PRTG S EOD en TEPER SE OTe mo EE AN 60
delayed hemolytic transfusion reaction, ...........:cecseseeecesseeeeees 459 reverse transcriptase polymerase chain reaction,
systemic inflammatory response syndrome mediator. ............ 459 transplantation, ...
C5a WIAEMINY, occccicnssceceee
filtration, E
PN ersecta ater see cen cinaa sopaansaracndsnctoassesyssteenceeeanageutncseequsctarsapaseted 16 INI ficiciciiiacccessitinnethnninichersensiniebatiel acimeactoeniaadanae l
C733G (Leu245Val) polymorphism 550
allele-specific polymerase chain reaction, .............:ssecseeeeeeeees 951 262
PUCIUU NINO TAIO CRIAEEUTOCACUIOND occa cccscsescaseasessssessssstsoreuscoascosecsosansases 951 499
(GalibratiOn DEAS; «.<..0....0..:ciessseces scdeausoe oe CD55, c
REN CONIA Os WEEEES <5 ss ededacie cess cosandssaensc¥seadaunsschonsdeceesssoatesass 316(L)
Canadian Apheresis Group, national registry of apheresis, ........... 834 I orcs canes odes cc atliecnicuvntcasenasnasaccacaiateoriagaasateaniainatonmnadiys a
Cancer CD62L, granulocyte—colony-stimulating factor, «0.0.0... 363
immunomagnetic selection of CD34+ cells, CD64, granulocyte—colony-stimulating factor, ............cccsseseeeeeee 662
prediction of CD34+ cell collection efficiency after, Re eases h apsni ece vos ccssixpaanis palaces town Guasssactededenaneateates
transplantation, hematopoietic recovery, CES eck ssnsceiesse.
Carbon dioxide Rs vcdccassnetexs a
production by white cells and false-positive result in sac Ecs big casa Ses ccarkgdo neanenacasdasvosdantanasseasnes saelnicecee reitnaiel 1082
BacT/Alert system, 1090 CD114,
red cell transfusion, ... 602 i)|s ee ssa
Cardiac disease, autologous blood donation, safety, ...................+ 669 so caw sca cupe ccaeasawnsncesoecetaboanceckanssdsesssiobanssgnsssseunaataanivateamuaseeen
Cardiac surgery RNR ooo ivd rank anciieagsdcotusucteatsasinsaastainephdessaktcat iasssmamadametdasipmcattaanaaae
<UUMCAIISCNDUNS EPID CLOITICNOED, 550.2.<5cacsasetconssssccendocecssassassnsaconsescones 669 MOR ods csp ccsv ences sueisassivanssudussnaccasntaaaubtacdadennosaacsuessabianaassadacheahdeedens
prevention of graft-versus-host disease in Japan, .............. 1118(L) 2) IESE SRS ena Wr cecee ia ns ner sre RT esl roe Bier ee Per
Cardiopulmonary bypass, lung transplantation, ............... 12, 1119(L) CD140a, ... eee
Cardiovascular tissue MONE ey ciiac i saitca cicacoalpd os skcnisanaciedgaasaemsucssdepvenacaaalssioonniagievbaelcisnee
PURINE ise oor cea coos isscps acs dsadansa cdl sede cabeceesttind tnd sadascstedcetlonionts 975 CD141,
B antigen, 75 CD142, ..
Causal Investigation Report. .. CD143, ..
CD 11a, granulocyte—colony-stimulating factor CD 144, ..
CD11b, granulocyte—colony-stimulating factor, .......... cesses 663 CD146,
CD13, granulocyte—colony-stimulating factor, .............sesesseeeeees 663 wees saasanis oe veces inelastic gpa cca asain aaa caaeaeoem meen
CD14, granulocyte—colony-stimulating factor. .... .... 663 CD148, .
CD16, granulocyte—colony-stimulating factor, CD151, .
CD18, granulocyte—colony-stimulating factoT, .............ccsceeeseee 663 SI cise seaca cian oma skccaaud evades Somtcadi Gia ecpaascaman anton sap evigaenatenledenaenINeS 499
CD32, granulocyte—colony-stimulating factor, CD153,
CD34+ cell, WA idl ease ccc asneratts i aspasecestas ees
COMNCCHOT CHICIGDEY) 0 5:.5sssescesscnsesscesnssicseesors 1046, 1051, 1063 CB155, ....
granulocyte, time to engraftment, ............ccssseeseseeseeeeeeees 385, 0163
peripheral blood progenitor cell transplantation CD157,
Volume 38, November/December 1998 TRANSFUSION 1135
SUBJECT INDEX
CD158a, cell selection,
CD158b, ... hematopoietic recovery, .. 199, 1063
CD161, neutrophils,
reticulocytes,
Column agglutination technology
A NCSA occas coscnascaccsttrcvesuavctncsecsiss Sastectsccesssisidecdasees 959, 1037
TAD INNIS, Giaa dons Zacekeaosiconsesal scyasse vtsanlcencsnavdseassacs ntacatesbseitinegab te 959
RNR oes ask vsssnscaunmocvesuen nsiassns6ats touctutancoasésecscdiuadanthasieangeenatneaneetae s 499 ISARRARA RDI rsicbon desc dasss assessacsceptsehietsvavascuavnsedssneisbacesareaiys 959, 1037
CDw123, ..... OE BARTOAmNe MENIMSD SELADNNOD cs acac astsb da ss deca soacpaveschcisosb caouacnme eeavek basen 959
ROM IIEND ic dcaieuCsheuisaoudss inaancueepc exeuncsedesecaaluat takeeras Coykuscteeecinisnioasruenenanidete s PIER NANO cadens osep aces su cese puedes dyctvedecsncadnesnyo daaeintbatayeavcen ’ 959, 1037
CDw131, 499 PS We sawR MI ED iss hs vcs asnssyccosuantnosc canassetud eSevvecae susveasseslivtebhece he 959
CDw136, ........ BO variant A antigen,
RNIN Aliga tossgcsscasnceiusatdenvetvesvensvanasveccne sseeaetnauseciiohscvemaneskuonasmceor be ta4 99 NAEPSNRERNS AN AREBEIN ,f oc p ccusssccssevasss saxuicd lcnasvissivssvives cvesesacessaneedecbossaceyes 959
RNR css encanta ces ncatanpbxsoecetocts ced etiacesant cess eetemmaseReemaESID A 499 WAS MIE osf eces cos icap.soan cchsctasSosseidiequiacesouesskapaseinedeabcbhadccestGGN 959
CDwiAs. ......... sere Cicer aR 20 6 ines cj sadec cssvsp Se biaivessvceibacasssacaveucestacceutiesceceees 959
RONMENT ceeo tis es onico tesdacscvasctsscsbapsetesbaxinceyadesr we 499 Commercial acid-elution kit, low-ionic wash solution
Cell number PURINA esd do ciicasao n czeacncesioosvsdctaabenasssctupsvasasesstoiinrdceanasbacasosetanten 56
dimethyl sulfoxide, ; antigen-negative red cell,
second messenger effector mixture. ...... D+ red cell,
Cell separator. See also Specific type az D- red cell,
SemR NR Mins Fasten sees Paces ah sae ans paunbs sap epsnenjasdasessay anes a oebeasecatenyets 24 false-positive eluate reactivity, ....
RAED NNN ARI 2s dos psucs Secksacedesecossoncessanncsscaessovecaagavabens ZOO) WOOL IgG,
Cell-free plasma, human immunodeficiency virus-1 phosphate-buffered saline,
after storage, .. COMMMELCIAN DIO RVCIOMA EC RIED). siciccssscsnesessssssedesssectsasoncsaisusasesasensvaves 56
compartmentalization ofhumanimmunodeficiencyvirus-1, Committee report, solvent/detergent-treated plasma,
immediately after component preparation, ............csseseeeeeeee 580 development,
Central Africa, human herpesvirus 8, prevalence, ............:.ssseseee 771 CERNE o cae cn casa Sorat pcb na casa cde ean Sedu case tae uaaniacacseuagucaveeuaveey
Central blood volume, red cell transfusion, .....c.cc. se.sse.sse.see.eee.eee s 602
Chemotaxin logistics,
PIN NPENIS yo sdsesoo sco acs nsbecsubscesassosussanoeanstsosnSae adbabpaapsansasteanenecsbeiosn e 16 production,
NNN NURIA MMR IIR 5256 5g css nck dudvucsd ccatnnssdnaSvascncsoasoscensretunhrages 16 SONS oooso s viescsacocaa aise ces tv asadudanpausbdacusvesshcnece cusbeensinadinusetesennssegas
NRE RIIRRMEERENED 525525 s0h<2écovspensivaccorasesd ssuiccscsaccupscccesbsshaabven steams 16 QERINIIEN sc acucieees aka covets tnasenisceans bep asser enastikeguenerseses
Chemotherapy Common source-plasma pool, hepatitis A Virus, .............:ececeeeeeee 573
RNIN po 2y oss ccgas a ascavsccocte ceuekicenhcubdhcciacastesdsMeciesoumontess 722 Communication, blood donor,
peripheral blood stem and progenitor cells, .................0+ 209, 1046 Community service credit, blood donor, ...
Child Compatibility misinterpretation errors, ................0.
PANINI coh hcscs sas cose bau se ocasastcupcupaonresvacsscuavcoscktensveciauoeaaseeeeey 944 Competence of nurses in bedside blood grouping, ......... 999(E), 1030
GB virus type C Competitive reverse transcription-polymerase chain reaction,
oe, | CUR RRR NGOS 0 2 oS ccs csp eand cts sds Sng resins caveventaectacsvasebecsishventsinense EON
Chromium-51 red cell survival studies, .. ; Complement activation, buffy coat platelet concentration, ............ 16
CSE RENR NARS RRC BEEN ETN sack Sasicnsncescissnoesesncosdseciconecoseswaystunss 247 Complement component 1 inhibitor deficiency, hepatitis G virus
Chronic viral hepatitis, hepatitis E virus antibody, ................se 589 enzyme-linked immunosorbent assay, ..........::csessessesseeeeeeeeeees 307
Re INN NTE EMEN ASIN, 5520 cs ssciescsvsosnoncsenconesonsessesonssezecssndsisasorescnscevseeen 24 nested polymerase Chain reaction, .................sssecesssssssssessessesees 307
cisAB blood type steam-heated plasma concentrates ofC 1 inhibitor, ................. 307
A transferase Confidential no-fault reporting ofe rrors, ............:sceee 999(E), 1071
Btransferase, ............. Consensus conference
Tey sipingfn ROSE IS OS eg OIE ORR BRE Peeve Oren 441 ORRT DOENS 58dsc psiss stieosenscssseonsnde occe5snsatessax eiecasts 97
SUETNRSO MNRIRN INNORRG 6o so 6555 Secisnsecneysbivivencssbasncicnsspsesesucvscaresiceusectsa 44] Aten Aatal Ant-D) PLOPHYIARIS), 3...06.6e5sescicasecsissessescesossessssasessest 97
ROMRNR Cab Sc ccnescoscsintesssacsns ethical considerations of anti-D provision by immunized
SPINES CHRRNINOS 5os ssceccca ns honsnasevegsianaioscnaassocazcvaysahisesveaoeoeessonere 44] NORM IRE Roe cao aceat ars veseces ck scucacsiccoscsac colubodscawsaubyaeascenonssienen’ 97
AORN oi. ger soso nccchsieswansase suse cdexes covei pasbbessvnsiansiesersantiatesssherecatores 225(E) SUR RDRIRID fata ocs ns sored sd cancconsesudacetaossus coucsueasuscvedinssveabanesisacieeNensiee ¢
I es tL dessa basS cans enaeiboackevendoaat persed io ticeaseasasedotiogusctnconios 318(L) immune-mediated thrombocytopenia, ..
Classification of causes of errors in transfusion, .... 999(E), 1030, 1071 monoclonal anti-D,
Clinical Transfusion Process Improvement Project, ...............+- 999(E) polyclonal anti-D,
CPMNAURNNNEIE IPT TANNINS 5. Ss assctneesncisasnonsccenssdinessssneseeassea aces OU) unrelated-donor bone marrow transplantation, .........
Clotting factor concentrate, hepatitis A VITUS, ............seeseeeeeeeeeeeee 573 decision-making,
ROEM NMNND os cons occ aha caee ctvesenadSiveracseviveress
ACEI; PHTAGICS, 5s ccseccessecssccsscscccsaccssssensssaseossseses DOO) 908 UE)y SOF: OMG 020 0c5sscstanieeascdcvanasseapesdiaaeces
Gobblestone area-forming cells, ..............:.0s.cssesesosessessssssscsessesessees 1063 indications, ..........
COBE Spectra apheresis machine, peripheral blood progenitor COIR oat ti stcd cies Kpivassvidencveeivatess e
cell collection Consultant, ISO 9000 registration,
ea MRNRAEIER I NNE 5s os cxtcas asSnscecsssdcaonsecdsnsecsiceshgctbsatseedsisaen 70 Contamination of sample for polymerase chain reaction, ........... 104
CD34+ cell extraction, ........... tO Continuous-flow blood cell separator, granulocyte, .............000. 5!
eee EIEN oo os cassssccosccccccauncevsssons egcesccesvesestansscoccaeaesl 70 Copper
comparison of AutoPBSC and Version 4.7 systems, ..............+ 1051 PPATINOIU WESC SRISCASG) cisscssccsccicsisceissssslsscescitecsconevstectasenens 32
RNIN osc los soos essccs vayansesasasdastbcaecheedeeissscabbilna b 70 plasma exchange, :
mononuclear cell purity, RISER scarce eas ci ssa cy rasC ates dias tasks tala cs puacaaensntenbe scott acaceadeeonetea :
PERGENEE COMME GECEEAGES, 5.1::00:<050:ahscvessenssacssoccosscsssscesseosooos 70, 1051 transfusion practice,
red cell contamination, ............ Cord blood banking
Cocaine, blood donor, 512(L) accountability,
Cold shock and white cell apoptosis, ...............:.ssscsseesseseeseeeeeseeees 1082 allocating cord blood,
Collaborative Hospital Transfusion Study, coordination,
Colony-forming units—granulocyte-macrophage, CD34+ current situation, ............. .
1136 TRANSFUSION Volume 38, November/December 1998
SUBJECT INDEX
ethical issues p-selectin,
eee ROI a Re PORE EE Be Te 867 Cumulative frequency distributions and percentiles, in reporting
WOEESHIOP GUITIIATY, ....005<:2:nsesesencssacacsosssssnsscosteees blood usage, 12, 1119(L)
factors influencing availability, ... Cyclophosphamide, peripheral blood progenitor cell
financial realities, .............-.eseccsese CD34+ cell collection, ..
harvesting, costs of mobilization, ...
linkage, engraftment,
oversight, Cyclosporine, 225(E)
recruitment, po, ee ONO U CSIR et ESCO Tee UTE Pr aee i MEST C TAC EN 951
RPI AMMAN TN p22 as sce cn accscccasiscd cant pep acces auaadnd svdcesaduaan leas 867 Cytokine
NRE NSD ic dk fates c ona dna ipatdacs una pnatbaos plesieaconbamcdvcesnbaaabbntes 867 febrile nonhemolytic reaction,
unrelated donor blood, National Heart, Lung, and Blood role in white cell apoptosis,
BRU GSE UROi sE MISORR IN ENUM occa ssisarsccsessennioneinsssasesssecacssineddaestace 807(E) transfusion-associated sepsis, 703(L)
Cord blood progenitor cell, storage MN 5 Cocos cha caslhns fon dsiniona sdaaecoeyduenasucasbesBuakdcasoatiellia 236
temperature, 615(L) Cytokine mRNA
615(L) IMAM CUAM MINNADNN abe cascada cases eo ctan Jadahicsthasseeedusdenicadesadaneasss LOO
Cornea transplantation, ABO incompatibility, competitive reverse transcription-polymerase chain reaction, .... 236
Corneal tissue Cytomegalovirus DNA, peripheral blood mononuclear cell, ........ 271
PAIR I etic dens ts cas sckven sid dosadonsLoguestessayeigibaua aaUiwecceoateeenpdaeios 75 polymerase chain reaction,
MU RMMEMETRUGD Wisp sess gik i 5 0%55 sou sand sallgndo ntiveseiiaualpeegtd eons rac Re ound cnet Aes 975 seronegative carriers,
Coronary artery bypass graft surgery, transfusion practice seronegative donors,
ANNE MAREE T OPMISA MOMMISNIED cs san 25scas ca canaguadababsdubscescatvogdhcenswstccasdstia 122 SSRI NUNN cs a a ds cts necator ck cce vale caicacaled 271
interhospital differences, ........... ey Cytotoxic white cell antibody, enzyme-linked
red cell, websectcaey SRAM RESNUIR NURE EIN 5205 Saccsa sc oacadasnaszearsvsustcscscsiusiuudiaauessaaseuadisaaee 41
variation by surgeon, .....
D
Corticosteroid,
D-CE hybrid exon 3
Cost-effectiveness, preoperative autologous blood donation,
allele-specific polymerase chain reaction, .............:sssceseeeesenees 951
CP2D polymerase chain reaction, asks ee
PAPERIR E RoN NNR NIL ON 56555505534 ctensct sacceansnvdansoasscancascasadieigcobaateeciasee 242
D variants, genotyping by multiplex PCR, ... Saooneeceecin ene
plasma volume
ENCtmE U N RRR ONI oi sana dncsscnscgcdensscasensessesncwsdacdencnbcoranes 332
aggregation,
Delayed hemolytic transfusion reaction
glucose,
anti-D, ....
ERUIIOUEIEIID SENDGE VESPODISCS occ ccsnsicscssnasaccvestsxcecensaapesncaagusnisereds 242
.. 1022, 1026
lactate,
1022, 1026
morphology,
ON 2a Sass aascncsdsscd casenskaesedcadsacsnssesasecsdcqredsuaacadasasedbasiel 459
C-reactive protein, ......... ... 459
(CERI ARNORINON R RNR RE 55a osc cnsbjssnstnen ste naatacceonnasanctiosacenes 459
GIN 2 coc ces de sa su tscbnon saseusisasdsnsknsdsndiccnactnnedaiatdesatdaccsanisisesuasebab 459
exchange transfusion. .... 459
RINE aceite site cians besctnscasasndcucsdustacinsseseuvsisedcbouatecisasaskeds 242, 1082 fibrinogen, 459
CPDA-1 packed red cell
hemolysis, 459
blood component, interleukin-l, ..... «= 459
storage, 24-hour storage at 25°C interleukin-6, 459
C-reactive protein RNR OUR oasis sceecond ca cdabsced tohnstacadcacasenreka ooestnancenatiosmusatorla 459
delayed hemolytic transfusion reaction,
interleukin-10, ...... 459
systemic inflammatory response syndrome mediator. ..........
RGN UM had tases can ae cabeaasaccssnadnccsaniasenasad Uascsengssiesmaeanaiieneriee 459
ON NERO ig gtcn sd sscicneces tended nenikouecsaaaaanapiaceosskewmnatous 810
septic-toxic syndrome, 459
hemophilia
CRAIG WORN RNIN URI osccnai a cimacac xan rvemsageersniaaonnca petiones 459
formalin-fixed paraffin block brain samples,
Depression, in donors positive for human T-lymphotropicvirus, ..... 1056
IN eRe ada ee cansntccacoesondatubns scascusasudciens tecseuasaiedsa kcsabiatabiionastueas 817 PIGGCCEITE SEMIRTEIVINY NOVEL, oo. ssscccecnessesnescenaneverwsostvacs 999(E), 1071
PRUNE rs c6 cst Scns taoansscotctctnaatt caccuasunscoatssensdccceseacesebany 817
Dexamethasone, neutrophil
human albumin, GRIN oa etn ao pds Sassen gu loaaebespemng 713
UN PRICE Clore Sek cd duc snes 18 0nsstniesecnaisucziecacaebuccauinoadionanoaen s 221(E) bactericidal activity, 713
Rui N 0 oS is 5s boda Cocusuntnaciedenceaasbesataececetees 221(E)
donor pool size and risk, ......
RRR eNO Gace oscsnsctdsess dactnendabsnaddesuieisividswnncesecets 221(E)
Creutzfeldt-Jakob Disease investigational Lookback Study, .... 622(E)
Cromer blood group antibody, hemagglutination inhibition,
soluble recombinant decay-accelerating factor, chemiluminescence, .
Crossmatch NUS cd ohosicciccatcesngnctentins a
I I 9 ics Sco ag astsect tSi dsabasdvens scsaniesis ids Napsacedesdncecatsens 959 SETISTIUTRNUCTICNAG AINA GSI, <i css ssccnssdncsecanncentaccnsatiennes
column agglutination technology, . DI a cesses aces ais cenacg ch niscikcs tsspz sdenccainarpunnnctdemaiacloemadaibants
pretransfusion testing instrument, morphology,
Cryoprecipitate, transmissible spongiform encephalopathy, Dimethyl sulfoxide
Cryopreservation, blood component cell number,
dimethyl sulfoxide concentration, extent of shape change,
SECONG-MICSHEIEE CHOCIOTS, ........<.ncecsssvecnnenssocssetsesonscrescesseonsasues 160 hypotonic shock response,
single-donor platelet, percent ofd iscoid cells, ................
SIMI Ad Siichdtss ins siasicasasesiisenadwacdsieakoideahiudasdseaddegsicaastaciesaus¥s 160 p-selectin,
CS 3000 Plus cell separator Dimethylmethylene blue
peripheral blood stem and progenitor cell collection, .. 1046, 1063 DIGCTRNCINDRNAINE TRACTION, oss... seccsncnsesaswevssenesesssosenneeess 7
platelet, bacteriophage R17,
gender, .... bovine virus diarrhea,
Volume 38, November/December 1998 TRANSFUSION 1137
SUBJECT INDEX
encephalo-myocarditis VIFUG, .................c.sssecscsessceecserssseseenssesees 729 Duffy (Fy) blood group system,
phenothiazine derivative, FY glycoprotein,
OREUIGDTAINIES VITUS, ...5..--<c50.260cessoscessees Ethyl palmitate,
red cell, European Acute Transfusion-associated Hepatitis
red cell potassium efflux, Interferon Study,
vesicular stomatitis virus, ..... European Medicines Evaluation Agency, Committee for
Direct antiglobulin test, Proprietary Medicinal Products,
delayed hemolytic transfusion reaction, Exchange transfusion
red cell-bound immunoprotein, delayed hemolytic transfusion reaction,
systemic inflammatory response syndrome mediator, systemic inflammatory response syndrome mediator,
DIT RR 5c ccvs asics ccicaciyicamiczasncisaiespeotedesensvicasoevanes 999(E), 1071 Expansion of CD34+ cells,
Disseminated intravascular coagulation, antithrombin III, Exponetially decreaseing theoretical distribution, in reporting
DNA electrophoresis evaluation ofw hite cell apoptosis in blood usage, 12, 1119(L)
SRNR ooo oc oce cans ct adensemsessscstcetbbelusaceesessasieintooaatastAldéoesta 1082 Extent of shape change test
Pae p NNNIBRNEERNIESD N 5255.55 <cstscin jo tid yd sncscyacsnacesieevacscavenineetsensantoaneca 118(E) dimethyl sulfoxide,
DNA typing platelet
Fcy receptor IIA polymorphism, iced iie sateen cepa tanscun gma nesusieesesassventkusasasavanaxacieatstaayeusaies 31
peripheral blood, patients with potentially modified patterns, .... 510(L) multi-laboratory evaluation,
Dombrock blood group system, 1022, 1026 reproducibility,
D-positive cell, maternal weak D variant, sensitivity,
Drug-induced deficiency, antithrombin III, second messenger effector mixture,
Duffy blood group locus, allele-specific primer polymerase Extracorporeal circuit, antithrombin II],
RINNE Sasscpnccccscsibestcatclcissecinccsprsenst chscotadessshteteseassvesestciocses 118(E) F
Duffy (Fy) blood group system
Factor IX concentrate, hepatiAt Viirsus, .............c...ssssecscsscesesseeresee :
allele-specific primer polymerase chain reaction, Factor VIII
MMM ITMID EM IRAAMONN 5S acks cscoc ets Scncicccoab Vases cosectsdesivsneavcaeubcemsacvaveces 168 LGM MRIRI D coi st she ovoussa cans surscctaluesuvavsisnincnscsacbtvecoaciisassndredspe s 573
RONNIE oS aoc ccc soa ndseSodods con aecinantisubevnceetanantbenaseonecs 312
transmissible spongiform encephalopathy,
E Factors in errors in transfusion, ............:.:ceeeeeeeeees 999(E), 1030, 1071
E2 protein antibody, Fas and Fas ligand, role in white cell apoptosis, ...............cccseeeee 1082
Effectiveness of quality improvement efforts, ........ 999(E), 1030, 1071 Fcy receptor IIA polymorphism,
Eindhoven Classification Model (Medical Version), 999(E), 1071 allele-specific primer polymerase chain reaction, ..............0.. 174
Elastase DNA-based genotyping method,
delayed hemolytic transfusion reaction, functional phagocytosis assay, ;
systemic inflammatory response syndrome mediator, Fcy receptor polymorphism, immunohematology, ................00+ 174
FcyRila receptor, allele-specific primer polymerase
Encephalo-myocarditis virus, dimethylmethylene blue, chain reaction, 118(E)
Endothelial injury, thrombotic thrombocytopenic purpura, Febrile neutropenia,
Endotoxin, transfusion-associated sepsis, AMIN sagas aatosc aries ppd ahaa Seeker ronsatobos sls vsieuvadsase dosteanscvcegnkiiecs OR
Enrichment of CD34+ cells by immunomagnetic selection, Febrile nonhemolytic transfusion reaction
Enterococcus faecalis, apoptosis as cause,
Enzyme immunoassay cytokine, sacete
hepatitis B surface antigen mutant form, GUINGERGE R OF DEATENCUSIOTOIG, <a... 505sccssesessercssssssvsssonsavasasessaneavasere SES
cy SLL a HUIS SSO es Sere eS nea Pe ere 194 lymphocytotoxic antibody,
human immunodeficiency ViruSs-2, ...........:.ccseseeeeeeeeees Feedback (detectability ofe rror), opttuateonscudsbayal 999(E), 1071
Enzyme-linked antiglobulin test, Fetomaternal hemorrhage,
Enzyme-linked immunosorbent assay gel agglutination technique, 177
cytotoxic white cell antibody, immunohematology, ref i 3
HLA antibody identification, screening, 177
AEE RN NINN 5 cs sascsesonsnbscictvnsbosnsonsacstussusscevssieses 4l Fetus
HLA-A locus specificity, PAE ERMINE ooo 3 49-0 coed uesasecei cusksbeatadcangt oan qnciviassnsasboaaunsoicssvscecessseesetselee 975
EMNIaB UN AG CIMMMEMII 5, 5 ss5esccsccnecsosascnccbntosesueunsosatastecatocceacsereste 41 MU SCURNR elipse r seicp scott oatss ara anak anes ta cases nasttkc ose SovcuscupnbaecSiueseleyustooh S75
IgG anti-D fetal cell detection, in maternal blood samples. .......... 749
GUN MMNMARI ISR SUEROTNNSS 5s dcvece stsancsnsse stocesoxaspbonstsbontonceeys 252 fetal hemoglobin, 749
quantitation, fetal hemoglobin monoclonal antibody, flow cytometry. ........ 749
IgG subclass Fibrin deposition by platelet substitute, ..............ccceee 997(E), 1004
alloimmunized patients, Fibrinogen
quantitation, delayed hemolytic transfusion reaction,
SURNN TNENSEMURN IEN 0 ope csss ccs ccscesastiacensscsiessvonusncsvinesucccontesdenshs 4] systemic inflammatory response syndrome mediator, ............ 459
non-complement-fixing HLA antibody, Fifth disease, 108(L)
nonspecific hemagglutination, Filgrastin. See Granulocyte—colony-stimulating factor
red cell-bound immunoprotein, Filtration
thrombopoietin, blood component,
Enzyme-only blood group alloantibody, pregnancy, 318(L)
EXEOP PEDGLANR SYGICIIG) «x. 5accssseassscisscecncsscoosseacondsvoses 999(E), 1030, 1071 interleukin 8,
Erythropoiesis, autologous blood donation, compensatory leukotriene B4,
PRIMNPI EMIR iscc oc sks ascsccéndsacnsecdsndiceusacbatinsndecubsdtneasabacspeacskocrkeesc s 613(L) platelet concentrate,
Erythropoietin, preoperative autologous blood donation, tumor necrosis factor alpha,
Escherichia coli, Fe ES Rg an a es eR EPR rs 317(L)
Ethical issues, cord blood banking
conference report, Flow cytofluorometry, red cell-bound immunoprotein, ............... 782
SUNS MNMR DIN INNIN 5555.05 ise ssSs<sadesdasdsotssacasadaoniecessenscesotbacetoeias 867 Flow cytometry,
Ethnic population detection of white cell apoptosis in stored red cells,
allele-specific primer polymerase chain reaction, fetal hemoglobin monoclonal antibody, detection off etal
1138 TRANSFUSION Volume 38, November/December 1998
SUBJECT INDEX
red cells in fetomaternal hemorrhage, nn CT TOOT TE TEE OTTER OAD
platelet, fresh human platelets in rabbit model, hepatitis C antibody-positive donor, ..
p-selectin, HOCH GEUG USER, ..:ci.cescsececescessessesee
Fluoflow cytometry, white cell-reduced platelet concentrate, polymerase chain reaction, .....
Fluorescence microscopy, platelet, pregnant women, =
Food and Drug Administration reverse transcriptase polymerase chain reaction, ................+0+
blood bank software SON sos Sst csraticmicsacinn
GSERERSMNE SOCUEMMREOTD SEQUUS 55 5s cncscisicsecsscceccosecuceacuacetscuesuassestansoee 86 testing for current infection,
internationally developed software, Gel agglutination technique
regulation,
regulation future. ......... D-negative cell, .. in
regulation history, BRP ears asec sas ycssac cnbasebuinSveccusabsucceasstosaatoeateaues
Blood Products Advisory Committee, SCUUSRERARRCUUA NC RUIANIINA EGN ssi snsccnanencaecsansansscbavassdscssnbaacosacs
error (event) reporting System, ............scseeeeeee 999(E), 1030, 1071 immunohematology, on
Forward ABO group Kleihauer-Betke test, compared, ..................cscscecssescscsssreceseseesese
aN IN lai Sapincia2e Sse, Pog cans was evav Sainte cocacn codcass ncsepens eeealanoe 959 RUN NURI MENRD NN OIONRINY Gs ess asics Sci cexesines cceictibvassscdasRadundacoeeasetie
column agglutination technology, ss 959 Gender
pretransfusion testing instrument, p-selectin,
Fraction I+II+III, transmissible spongiform encephalopathy, transfusion practice,
Fraction IV, transmissible spongiform encephalopathy, allogeneic transfusion in cardiac surgery, ...........
Fraction V, transmissible spongiform encephalopathy, allogeneic transfusion in orthopedic surgery, ....
France CR eas sisstcssseecsksascecdovdecdicccesreccesenasins
DOASIGES DIGOR GOUDING, 25..03-66cscs0scccescsscscaccosscacstccsseeenee 999(E), 1030 fresh-frozen plasma, ................+
mandatory hemovigilance system, intraoperative hypothermia, ...... ce
nucleic acid testing, NUM ois daca shan ess dal ainescaadvuinivisiaciebcdvess ae
Frequency distributions in reporting blood usage, preoperative autologous blood donation, ...............:.:ses0 392
Fresenius AS104 apheresis machine, peripheral blood CORA NII scacasscior cade kisash palace i pecabines 1063
progenitor cell collection General health, of donors positive for human T-lymphotropic
AP ons GRR RINNE N55 can natsvenscddcpatsesannssasscacestenensbassestceeee 70 NUR ics os our cea aoc Sapp tess ppabencstpsnasbnsn Ss aaesclenonoasanaeneseeness 1056
A re NN RNIN se ccos scibuc esstead anc sonics rowstasndvscaciusudaonstaded 70 General Well-Being Scale, 1056
CD34 cytofluorimetry, .. ses 20 Genotyping, in Rh blood group system,. .
extraction efficiency, Glucose, red cell, 24-hour storage at 255 °C. 424
PIR MIIRTIR EU OE IUMETEY 5. n ass nsn os ccccasceiscecscisaseoshiccccccsscescssysdacnaess CUI NG si aes Aacec capsid swe cdasascne bata asada abana 429
platelet count decreases, .. Gly,,..»Ala substitution in human erythroid band 3, Wu blood
red cell contamination, group PIII 255 ascetics casa ccaccvaeassoaseaticningisotnaasutavuad 745
Fresh-frozen plasma, Glycophorin A
irradiation, I NN ne dc ciaoa oon se dac a Sy sees sn wsslcaca ipa straec ae sasavenb onan ectaeovbesenianiess 658
white cell N-allele, ws GOO
fast filtration, Glycoprotein Ia/II receptors, .......... .. 997(E), 1004
filter capacity, Glyocprotein Hb/ Ta receptors, ............:..scescsesssssesecoseasace 997(E), 1004
NNN 50553 Sal cacasnac Su daca cdacans Scacengebcailenteacdamnaciodeocia 645 GRCOMEOUEIEE TD ROCCO, isc. sca cacccsaineseseascessesincsescesesaces 997(E), 1004
hard-spin method, ........ CORN Ie acoso cass cannsenccesesenicscacitxcsntsnrsscaiosomeattoaeieicies OOM
SUPRISEPU MMIIEMER ISOM 65 osinciskosascasacinnescacetutecsdeereossdbacxcabsaacaues 645 Good Manufacturing Practice, collection of peripheral blood
slow filtration, SORE ANNA ORION cscs scesecsicsccsznnesietnnaccadttestaatioucedeesessit 1051
soft-spin method, Graft-versus-host disease
white cell-reduction filter prevention of by irradiation or storage of red cells for more
UN eons cocoa cvs cexsiosonsbochcusdaascoascasianacateasessieolsakacaasee 645 BNI RIE RIN Foes cactecsescensscncecectecacadsacsnancspbentammontense 1118(L)
filter capacity, ... Ps... SEAR CU RES CE 1f eRe a See ae eRe Peer ace ae RENO errs 247
flow cytometry, gg EN EEO OIERS OT TRO TOE OOOO CORE 999(E), 1030, 1071
SUE RIE RINE ECEDOMONS 5555s cscs sdck oct cccacevesascsavecdsesndsdtiases s 645 CG casas gales aa cocconeccta nanan eoncemmetecnoebeaestebinds 650
slow filtration, apoptosis in stored red cells,
soft-spin methods, ..............0see0 CD34+ cell, time to engraftment, ................scscsscccsssscecesessscscsssaces c
Fulminant Wilson’s disease, copper, chemotherapy,
Functional phagocytosis assay, Fcy receptoIrI A polymorphism, ... continuous-flow blood cell separator, ..............:csesessesesesseseeeeees
FY glycoprotein count as predictor of CD34+ cell collection efficiency, ........... 1
allele-specific primer polymerase chain reaction, GORI ERee CIRNEN NOR sg iss ccc ccs seas cesses ccasenitnteuaadsieisocien
ethnic population, FUtHTS THANSHUSION GITOCHONSG, ......20.5....cc1.ececcosnssseesessnsaestncvases 77 10(E)
molecular basis of the three major alleles, granulocyte—colony-stimulating factor, ....... 663, 722, 1051, 1063
G SUMEIRE RNEN IE OO CINE ssc cada siceck ctcdsnacsancssoccassaceciooemestnsioretas 557
G1006T (Gly336Cys) polymorphism prednisone
allele-specific polymerase chain reaction, ascenscs sadec vea sncc a sande oasniartaos
DORVOOHASS CHANT FEACIION, <....0:000sc0ccsescsncsiseacenaesarescasosssonnceaseesess 951 NNN ssn cascada snscskcs Scns SaecuiomcoecteeescemenNeeao n
GB agent, blood donor SINAN RNIN PORCINE ccs nv ansacas seca dan cgeneatensenedonampceman
infectivity, WURUREES CIEE COUNINE 555 sca ccsiessicescncdssscececeeecics &©nnNN NDhDhehO
URN eich ei fas ca Saco so dcbcvasyccucasctacaccs easgenconsorsareencoipeean 290 Granulocyte—colony-stimulating factor, .............ssscseseseeese |BY 10(E)
volunteer blood donors in Taiwan, apheresis
GB virus type C CUMDERUUNE RENE COINS oases sssccciscncsazicteniacncenssens 1063
SRM ET EESTI OICISES 505 5o0.cnes0sseysénccscessnexeveosineoecsusancsecsaeensces 378 granulocyte collection efficiency, .... 557, 1051
anti-E2 enzyme-linked immunosorbent assay, granulocyte collection yield, ........... 1 J J
Australia, hematocrit, :n g
children, RAR AMN RI CEE onsen ctncicsaenaseeceusoaseciarnimeteenenee S
evidence ofp ast infection, platelet count, ................0. 57, 1
hemodialysis, I aisgras taectaapeneatradnne acmmasaeesepetad aNnaFwnSg
Volume 38, November/December 1998 TRANSFUSION 1139
SUBJECT INDEX
Hematologic disease, effect on bleeding time, activated
Hematologic malignancy, transforming growth factor B,,
after transfusion ofp latelet concentrates,
Hematopoietic progenitor cell transplapnlattelaett trianosfnusi,on , ... 839
clinical factors influencing posttransfusion platelet increment. ...... 839
HLA antibodies with restricted specificity,
OC OLE Poa,CE Re peeoren er AE E er 60 platelet antibodies,
NEM MMER eyc gy uc scucksttey Sinegeuissandcby sujessncpsins Recsucetaabed dadavankanchsriokerapvieeeeess 663 posttransfusion (16-hour) corrected count increments. .......... 839
RIE ia caeiona cecscascuisvosie Cicazxennvaneschnscsapecacciekssusbevede;Suabaecnligsecessneaeengl 663 SERAUTN NC MRIR INEh i io s5 ccc staesndcabitave svete innavesiestisseiseacatneebeavs 839
granulocyte, serum tacrolimus,
comparison 722 total bilirubin,
evaluation, .... 722 total body irradiation,
SEPTATE COIOCMINOS 5s s scssniecosisicnssnscensedsnssconbatinibnssieceusshe 722 Hematopoietic stem cell component
white cell counts, 722 collection, 1046, 1051, 1063
multiple daily doses, 663 processing, 1(E), 1063
neutrophil transplantation,
OPIS EG pcs cosn os ascusunshncvasicnans sapseacceatecseuastesemenanne 713 Hemodialysis
RIC RASRADAISAAN CRIUEL onus ssn 0cnsassuiscosdesonssdaicutonssepccvervecereaseuauss 713 RRs MMMM AION ys clits Sea sucess nhdsae sang dutta dvacas can tasias AaeenNeads 821
ROD 5 css tavacvc chess cesisbasuckl cesiennseousians son as EE 713 PACPIANAENS Ey Var AS QUMEROCLY) 55sec siccccesssstes Scbesevtvacsvecnsssvacoiasecdnectee 589
ROE acne oie cc cpesubbbsesbavastbakapentssueatol tcvevessusehamiuadivalgremmausaieeseys 713 BORCADRe R Nes WENCU Bs ects resect bach sS acess sais Rass, scnah aa ascas Case noueey
UNM os chc cy cotincannin easeuSsastap on cedndetnawamhirsavonnckuaiiterseestaaonakdsenesr 713 Hemodilution
CD32, . iS intravenous perfluorocarbon emulsion,
C64... .:..:. tia left ventricular pressure-volume relationship. ................:.:0000+ 13
chemiluminescence, 713 myocardial contractility,
AMCHONS, .........:.:.. organ tissue oxygenation, ..
immunophenotype analysis, PCTEUIDYONS 2.55.55. seictesssese
MMM 5 25 ccc sscatdssbcaosus ease ecsenpeakecsachcn catnndech dohenspseunsaneassievse 713 systemic oxygenation,
IPMN INN 5s pac Soca cp uh gh cans Saasscndoncesscnwnatapseisoeastapiaenesiuaed 713 SEIN ee CLIN sos casos sad acbnescenk vans nt ckcabetapaWiscexcveuiwedivdedenstadecege 145
neutrophil antigen, after LOGAayS, .....:....:.c.cssciesssscovevsessarssesessases 663 transfusion practice, 35, 145
neutrophil-specific antigen NBL, ...............s-ssccscsrsssssessosseseseesssss 663 Hemoglobin
peripheral blood progenitor cell TRESS BGO MARENT EUERDLO ILO INNA 5562 cc ccasessedssdacdesibcedsedsvacwadeteccdsedeseuseas 51
CIPSE e CEI CGMECINONY, oni... ccscencnscnsscssensecesssesnesece 209, 1046, 1051 ina e ly a neeeC NER ee oo 5]
costs of mobilization, blood donor
UMNS RINRNMEERIN (Siok cosa gb i Ss nic SssisoncscavsacwatedonseddtsVeundtiacobeabitves 209 GAUSMEAUNSEE RA N CLCE SREIAD S5 c csos s sf sacssitssncseescsbiadsestvaavdesancvaacinasisebuants
Granulocyte-macrophage—colony-stimulating factor, female plateletpheresis donors,
peripheral blood progenitor cell frequency of donor reactions, ...
CD34+ cell collection, hemoglobin cutoffo f 12.5 g per dL
NNR RIENCE oo coescsczsasseiaveeuddiosusa svsecusdtaas sasssaacentacoene nd 209 standards of the American Association of Blood Banks, .....
REMMI secs psec cs ns asacxavesssiessccetcupunsbeuscessavadssakestanietiaye 209 NORRIS cases ax sssca ca vava Wroeen cates ee cpa baauaraagucs: fae svodeckaasisvotvaccreadactanesasette ‘
Granulocyte-macrophage—CSE, ................ecssessssesssessesssossesasorsassnesées ] as indicator of red cell volume deficit, .............:cceeseeeeees 302
MNP N AMEN ce cet cours issaacebcasencssisidupicuecessensuvauskusoaatRasicavteees 247 BINST RG Pa AIREG RID gs casas 25 os Sea uses vcnsdavsn awcqeonesdascdacaastocness 6
Rp MNNIND 255 2cs ccs es voncosectac aciseseccssabdaancdsaccstesncesstasbedestaesesebaccontl 247 SE ener Na RN PORN I scot 0 2 hss ccascepstccsan Auten bunicdovsneluedentanieeys 522
ASTRO RP ANIMENOEDGID DLALDIEN, 5. 555.55c004sncesecssscnnn assascansconsnsunsbbcavissieeosteest 51 red cell-bound immunoprotein,
PREAMP OER EINANUNE c. Sop Sovecents so sesissdons cnene iveens nenicasosinsreeseainbieetst e 252 Hemoglobin F, hereditary persistence,
RUMI UMN 50255 5 Sg cca pkcsscgs sosknc senses ecainesed boastsbncavens eccenusea 312 Hemolysis
H ABO TICOMIBAEDIEY, <icscccsssiessvscssacessassassceocses 51, 999(E), 1030, 1071
Haemonetics MCS 3P apheresis machine, peripheral blood delayed hemolytic transfusion reaction, ................ 459, 1022, 1026
progenitor cell collection mechanisms in sickle cell disease, ............:sccsceeseeseseeeees 1022, 1026
ON NN UNIAN EISEN 0550.52 oss cho onnctnincscidsossenscasesucsvasceuelsccossecsscanes 70 plasma-incompatible apheresis platelet, .............c.cccsesseeeeeeteeees 51
See MRNMTTNIDINS acs cossicssncécsonsetcesovatnsesssvacsodicosvsibbesesne s sfO systemic inflammatory response syndrome mediator. ............ 459
pam MENARD RISMTE 5555 555:0 sscnncseseiaures vinzecadsnccasousedocsbisssesss 70 ERU RNES Es LARENEC ARDONA oss 2s sau aks cccen bk acd crag CasbdsSedatdsndecdeScuaas ts RENN
Bae NM IU RNR RII 085 ci saab vac sesicinisessabssennsstesekecds Aapisivenncoeee 70 ABO-incompatible allogeneic marrow transplant. ........ 225(E)
RD NINN MEA TRRIRIINON 5 occ sceue casesc scsscsestscsteastiapscmeyitveatucohssaetanss 70 autoimmune hemolytic anemia, 225(E
a PaRMARPE URNST RAS MP 52 5 os ecdciconsdcubsacovescdsvouseicasdssostacdesuasbceisins 70 bystander immune hemolysis, .................s.cessecssssssssscasee 22
Ppa NaNO INR UMDABNRMMRIDNI S 652530 sc sins pacsvagcesssniadnvsecsgevenbesstoueabeevcsubeus 70 Clostridium perfringens,
Health status indicators in donors who are positive for human drug administration,
PMU MMINU RINE INDIES WRERNE S css oc Lsnb tis 1 ches Socaccea vzsadaswssdeassiecieavctvooaenosee s 1056 hemolytic-uremic syndrome, —a
Heart transplant, ABO incompatibility, ......0.. eee eseeeeeeeeeeeeeeees o7 major ABO blood group incompatibility,
i ee PNNEIOMENEN ha caercn ose cscs Fasc pXenodsnicuixessacesseennsiO sCuaaytiuonrdeeaoaOte minor ABO-incompatible allotransplantation,
IgG subclass, y passenger lymphocyte syndrome, ............:.cccseseeeeeeeeeeeeees 27
Hemagglutination inhibition passive transfer of antibody. ............
Cromer blood group antibody, soluble recombinant solid organ,
aPOU STAI EEUOES 6. sns sic.de neveaicnse sxeccscsctn scortauilicie nonsense SO thrombotic thrombocytopenic purpura,
immunohematology........... ENG ANe SARIS cage cash ssi edsssvin sat zsanasioncatsahsiSesavunsecasstacessecenscbviasaie ee N“N
Hemagglutination-inhibition assay, Hemolytic disease of newborn, 25% J Dmo A(4i24 ii3d4 4 c de )
Hematocrit Hemolytic transfusion reaction
as indicator of red cell volume deficit, ABO THACOMIDATIOUILY, ssceseses.ccsadscvccscesesssecscacts 51, 999(E), 1030
as predictor of CD34+ cell collection efficiency, SUR RSRD acc2eat see oxShasle osuv en sniisa Asbup acsuccnanievcaceas teesabcud caxtepicaacanns 1022, 1026
perioperative myocardial ischemic episode, ..............sseeeeee 924 ERED ENOS 5s Socsdeictesai cnaoutssianbanietes ccwasaircviesss soiis tianaenSsosi 1022, 1026
SONU MNS NPN 95a saiinsnsrcnbcua seosddhatsishcckaycseba ucsss taniuseagbassaascivaaditete ns 924 anti-P,,
RNR a 055 tse Neutincactnspocpanss ieee euros OKT 924 plasma-incompatible apheresis platelet, .
EUR VERM E ss 5s0s rss casa cascghs vacate vs culeeanscamiast man Mostaens 924 Hemolytic-uremic syndrome,
1140 TRANSFUSION Volume 38, November/December 1998